Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Reported“
Suchtreffer
Begriffe & Kennungen
Adcetris · 4.8 · 16 b. Toxic epidermal necrolysis was not reported in the combination therapy setting. c. Extravasation may res
Eintrag öffnenAdcetris · 4.8 · 17 Febrile neutropenia was reported in 20% of the patients who did not receive primary prophylaxis with G-CSF
Eintrag öffnenAdcetris · 4.8 · IRRs, such as headache, rash, back pain, vomiting, chills, nausea, dyspnoea, pruritus and cough were reported
Eintrag öffnenAdcetris · 4.8 · In clinical trials, neutropenia led to dose delays in 13% of patients. Grade 3 neutropenia was reported in 13%
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · In interaction studies performed in a limited number of healthy volunteers, these effects were not reported wi
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.5 · In interaction studies performed in a limited number of healthy volunteers, these effects were not reported wi
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · The most commonly reported adverse reactions, occurring in ≥ 10 % of patients in the tadalafil 40 mg treatment
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · The most commonly reported adverse reactions, occurring in ≥ 10 % of patients in the tadalafil 40 mg treatment
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · The table below lists the adverse reactions reported during the placebo-controlled clinical trial in patients
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · The table below lists the adverse reactions reported during the placebo-controlled clinical trial in patients
Eintrag öffnenAdempas · 4.5 · Concomitant use with CYP3A4 inducers Bosentan, reported to be a moderate inducer of CYP3A4, led to a decrease
Eintrag öffnenAdempas · 4.5 · Concomitant use with CYP3A4 inducers Bosentan, reported to be a moderate inducer of CYP3A4, led to a decrease
Eintrag öffnenAdempas · 4.8 · Table 1: Adverse reactions reported with riociguat in adult patients in phase III studies (pooled CHEST 1 and
Eintrag öffnenAdempas · 4.8 · Table 3: Adverse reactions reported with riociguat in adult patients in phase III studies (pooled CHEST 1 and
Eintrag öffnenAdempas · 4.8 · The adverse reactions reported with riociguat are listed in the table below by MedDRA system organ class and b
Eintrag öffnenAdempas · 4.8 · The adverse reactions reported with riociguat are listed in the table below by MedDRA system organ class and b
Eintrag öffnenAdempas · 4.8 · The most commonly reported adverse reactions, occurring in ≥ 10% of patients under riociguat treatment (up to
Eintrag öffnenAdempas · 4.8 · The most commonly reported adverse reactions, occurring in ≥ 10% of patients under riociguat treatment (up to
Eintrag öffnenAdenuric · 4.8 · Summary of the safety profile The most commonly reported adverse reactions in clinical trials (4,072 subjects
Eintrag öffnenAdenuric · 4.8 · Summary of the safety profile The most commonly reported adverse reactions in clinical trials (4,072 subjects
Eintrag öffnen